Bitcoin Risks Further Decline Despite Rating Upgrade Analyst Perspective Disneys Star Wars The Mandalorian and Grogu Posts Lowest Thursday Preview Sales in Franchise History Older Americans Embrace Unretirement as Financial Needs and Purpose Drive Return to Work China Urges APEC Cooperation as Commerce Minister Skips Opening Cites Urgent Business Microsofts GitHub Faces Headwinds in AI Coding Race Amid Outages and Rising Competition Amazon Allegedly Generated Millions Through Policy Now Deemed Illegal Report Claims Fluence Energy Q1 2026 Earnings NarrowerThanExpected Loss Stock Declines CINF Q1 2026 Earnings EPS Surpasses Estimates by 573 Amid Mixed Market Reaction RVTY Q1 2026 Earnings EPS Beats Estimates Amid Stable Operations CSV Q1 2026 Earnings Slight EPS Beat Amid Mixed Market Reaction FIGS Q1 2026 Earnings EPS Surges Past Estimates Amid 96 Surprise IRIX Q1 2026 Earnings NarrowerThanExpected Loss Marks Positive Surprise OPENLANE Inc OPLN Rises Over 2 as Stock Approaches Key Resistance Level Thornburg Income Builder Opportunities Trust TBLD Edges Higher as Investors Eye Yield and Stability Cardinal Infrastructure Group Inc CDNL Gains 34 as Infrastructure Demand Strengthens GDS Holdings Holds Steady Near 35 as Support and Resistance Levels Remain in Focus Cohen Steers Real Estate Opportunities and Income Fund RLTY Edges Higher Amid Modest Gains Bitcoin Treasury Firms Unconventional Hiring Why a Doctor on Staff Could Signal a Strategic Shift HWM Q1 2026 Earnings EPS Surges Past Estimates Amid Strong Aerospace Demand Profound Medical Stock Dips 2 as Shares Test Key Support Levels Crypto Sector Shifts from Volatility Monetization to Disciplined Growth Earnings Suggest Samsung Strike Suspended as Workers Vote on Tentative Deal Amid AI Bonus Demands First FCF Stock Down 094 Support Test at 1759 20260521 Oportun OPRT Crushes Q1 2026 Estimates EPS 021 Tops Views Clinical Trials Day Gains National Recognition as 19 US Governments Issue Official Proclamations Ambarella AMBA Edges Higher as Resistance Level Nears Amicus Therapeutics FOLD Q4 2025 Earnings EPS Misses Estimates Revenue Not Disclosed Shares Unchanged